Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis

Clinical Biochemistry

Volumn 44, Issue 10-11, 2011, Pages 838-843

  Pawlak, Krystyna ^a   Mysliwiec, Michal ^a   Pawlak, Dariusz ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

Chronic kidney disease; Hemodialysis; Inflammation; Matrix metalloproteinases

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ERYTHROCYTE COUNT; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; INTERMETHOD COMPARISON; IRON BLOOD LEVEL; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LEUKOCYTE COUNT; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RENAL DIALYSIS;

EID: 79958856149     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.03.143     Document Type: Article

References (24)

1. Menon V., Gul A., Sarnak M.J. Cardiovascular risk factors in chronic kidney disease. Kidney Int 2005, 68:1413-1418.
2. Henry R.M., Kostense P.J., Bos G., Dekker J.M., Nijpels G., Heine R.J., et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn study. Kidney Int 2002, 62:1402-1407.
3. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Martin C.J., Murray D.C., et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995, 47:186-192.
4. Pasterkamp G., Schoneveld A.H., Hijnen D.J., de Kleijn D.P.V., Teepen H., van der Wal A.C., et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000, 150:245-253.
5. Chang H.-R., Yang S.-F., Li M.-L., Lin C.-C., Hsieh Y.-S., Lian J.-D. Relationship between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta 2006, 366:243-248.
6. Nagano M., Fukami K., Yamagishi S.-I., Ueda S., Kaida Y., Matsumoto T., et al. Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease. Am J Nephrol 2009, 29:109-115.
7. Peiskerova M., Kalousova M., Kratochvilova M., Dusilova-Sulkova S., Uhrova J., Bandur S., et al. Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?. Kidney Blood Press Res 2009, 32:276-283.
8. Pawlak K., Pawlak D., Mysliwiec M. Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis 2007, 190:199-204.
9. Pawlak K., Tankiewicz J., Mysliwiec M., Pawlak D. Systemic levels of MMP2/TIMP2 and cardiovascular risk in CAPD patients. Nephron Clin Prac 2010, 115:c251-c258.
10. Ebihara I., Nakamura T., Tomino Y., Shimada N., Koide H. Metalloproteinase-9 mRNA expression in monocytes from patients with chronic renal failure. Am J Nephrol 1998, 18:305-310.
11. Stenvinkel P., Heimburger O., Paultre F., Diczfalusy U., Wang T., Berglund L., et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999, 55:1899-1911.
12. Pannen B.H., Robotham J.L. The acute-phase response. New Horiz 1995, 3:183-197.
13. Rysz J, Banach M, Stolarek RA, Mikhailidis DP, Cialkowska-Rysz A, Pokoca l, et al. Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. Int Urol Nephrol 2009, Dec 2.
14. Tajima T., Yoshida E., Yamashita A., et al. Hemoglobin stimulates the expression of matrix metalloproteinases, MMP-2 and MMP-9 by synovial cells: a possible cause of joint damage after intra-articular hemorrhage. J Orthop Res 2005, 23:891-898.
15. Macdougall I.C., Cooper A.C. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002, 17(Suppl.11):39-43.
16. Stenvinkel P., Barany P. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure: links to inflammation and oxidative stress. Nephrol Dial Transplant 2002, 17(Suppl. 5):32-37.
17. Bisoendial R.J., Birjmohun R.S., Akdim F., van't Veer C., Spek C.A., Hartman D., et al. C-reactive protein elicits white blood cell activation in humans. Am J Med 2009, 122(582):el-e9.
18. Borden P., Heller R.A. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryot Gene Expr 1997, 7:159-178.
19. Baumann H., Jahreis G.P., Morella K.K. Interaction of cytokine and glucocorticoid response elements of rat acute phase plasma protein genes by C/EBP and JunB. J Biol Chem 1991, 266:20390-20399.
20. Chung A.W.Y., Yang H.H.C., Kim J.M., Sigrist M.K., Chum E., Gourlay W.A., et al. Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease. Circulation 2009, 120:792-801.
21. Musiał K, Zwolińska D. Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment. Cell Stress Chaperones 2011;16:97-103.
22. Pawlak K., Pawlak D., Mysliwiec M. Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease. Clin Biochem 2007, 40:81-85.
23. Kalela A., Ponnio M., Koivu T.A., Höyhtyä M., Huhtala H., Sillanaukee P., et al. Association of serum sialic acid and MMP-9 with lipids and inflammatory markers. Eur J Clin Invest 2000, 30:99-104.
24. Chou F.-P., Chu S.-C., Cheng M.-C., Yang S-F., Cheung W-N., Chiou H-L., et al. Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors. Clin Biochem 2002, 35:383-388.